Cytokinetics Stock Performance
| CYTK Stock | USD 67.93 1.07 1.55% |
The firm shows a Beta (market volatility) of 1.11, which signifies a somewhat significant risk relative to the market. Cytokinetics returns are very sensitive to returns on the market. As the market goes up or down, Cytokinetics is expected to follow. Cytokinetics has an expected return of -0.25%. Please make sure to confirm Cytokinetics treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Cytokinetics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cytokinetics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in May 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return 1.47 | Five Day Return (6.45) | Year To Date Return (17.97) | Ten Year Return 624.79 | All Time Return (28.57) |
Last Split Factor 1:6 | Last Split Date 2013-06-25 |
1 | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 03/01/2024 |
2 | Disposition of 28604 shares by Fady Malik of Cytokinetics at 6.67 subject to Rule 16b-3 | 03/05/2024 |
3 | Disposition of 5103 shares by Andrew Callos of Cytokinetics at 66.88 subject to Rule 16b-3 | 03/06/2024 |
4 | Acquisition by Andrew Callos of 16941 shares of Cytokinetics subject to Rule 16b-3 | 03/18/2024 |
5 | 2 Incredible Growth Stocks to Buy Right Now | 03/20/2024 |
6 | Acquisition by Robert Blum of 12500 shares of Cytokinetics at 6.67 subject to Rule 16b-3 | 03/22/2024 |
7 | Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference | 04/01/2024 |
8 | BofA lowers Cytokinetics shares target citing cardiology KOLs, market share concerns | 04/03/2024 |
9 | Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73 An... | 04/05/2024 |
10 | Cytokinetics EVP sells over 2.4m in company stock | 04/09/2024 |
11 | Disposition of 150 shares by Fady Malik of Cytokinetics subject to Rule 16b-3 | 04/12/2024 |
12 | Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil - The Globe and Mail | 04/16/2024 |
| Begin Period Cash Flow | 65.6 M |
Cytokinetics |
Cytokinetics Relative Risk vs. Return Landscape
If you would invest 8,274 in Cytokinetics on January 18, 2024 and sell it today you would lose (1,374) from holding Cytokinetics or give up 16.61% of portfolio value over 90 days. Cytokinetics is currently does not generate positive expected returns and assumes 2.8379% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Cytokinetics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytokinetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytokinetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cytokinetics, and traders can use it to determine the average amount a Cytokinetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0872
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CYTK |
Estimated Market Risk
| 2.84 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cytokinetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cytokinetics by adding Cytokinetics to a well-diversified portfolio.
Cytokinetics Fundamentals Growth
Cytokinetics Stock prices reflect investors' perceptions of the future prospects and financial health of Cytokinetics, and Cytokinetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytokinetics Stock performance.
| Return On Equity | -5.72 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (76.21) % | ||||
| Current Valuation | 7.25 B | ||||
| Shares Outstanding | 104.58 M | ||||
| Price To Earning | (37.76) X | ||||
| Price To Book | 31.90 X | ||||
| Price To Sales | 993.82 X | ||||
| Revenue | 7.53 M | ||||
| Gross Profit | (146.22 M) | ||||
| EBITDA | (484.31 M) | ||||
| Net Income | (526.24 M) | ||||
| Cash And Equivalents | 586.03 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 755.77 M | ||||
| Debt To Equity | 2.93 % | ||||
| Current Ratio | 9.01 X | ||||
| Book Value Per Share | (3.80) X | ||||
| Cash Flow From Operations | (414.33 M) | ||||
| Earnings Per Share | (5.45) X | ||||
| Market Capitalization | 7.22 B | ||||
| Total Asset | 824.32 M | ||||
| Retained Earnings | (2.11 B) | ||||
| Working Capital | 525.37 M | ||||
| Current Asset | 113.11 M | ||||
| Current Liabilities | 31.65 M | ||||
About Cytokinetics Performance
To evaluate Cytokinetics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Cytokinetics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Cytokinetics Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Cytokinetics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Cytokinetics's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (0.26) | (0.27) | |
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (0.69) | (0.65) | |
| Return On Assets | (0.64) | (0.67) | |
| Return On Equity | 1.36 | 1.43 |
Things to note about Cytokinetics performance evaluation
Checking the ongoing alerts about Cytokinetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytokinetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytokinetics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 7.53 M. Net Loss for the year was (526.24 M) with loss before overhead, payroll, taxes, and interest of (146.22 M). | |
| Cytokinetics currently holds about 586.03 M in cash with (414.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22. | |
| Cytokinetics has a very weak financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil - The Globe and Mail |
- Analyzing Cytokinetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytokinetics' stock is overvalued or undervalued compared to its peers.
- Examining Cytokinetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytokinetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytokinetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytokinetics' stock. These opinions can provide insight into Cytokinetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Cytokinetics Stock analysis
When running Cytokinetics' price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.078 | Quarterly Revenue Growth (0.15) | Return On Assets (0.34) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.